Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Metformin attenuates the production and proliferative effects of prolactin induced by medroxyprogesterone acetate during fertility-sparing treatment for endometrial cancer

Fig. 1

Serum prolactin levels during fertility-sparing treatment with MPA in patients with EC. Columns and error bars represent the mean ± standard deviation of the mean before treatment and after 3 and 6 months of MPA treatment. Wilcoxon signed-rank test was used and PRE indicates MPA pretreatment. (*P < 0.001). EC, endometrial cancer; MPA, medroxyprogesterone acetate

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us